At MedDay, we are committed to treating nervous system disorders in areas of high unmet medical need through the elucidation of metabolism pathways in the brain. Our unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism is critical in advancing novel therapeutics for neurological diseases such as multiple sclerosis, autism and Alzheimer’s disease.
MedDay was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer), who has 25 years of experience in drug development and clinical research in the pharmaceutical industry.
The company’s most advanced product candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis.
Revision date: June 2018